Abstract:Abstract Background: It was known that survival data were outstanding on several patients (pts) when the final analysis of the multinational, open-label, phase 3 KEYNOTE-040 study (NCT02252042) of pembro vs SOC for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) was performed. This abstract presents OS and PFS data using the same data cutoff date but with full survival acquisition. Methods: 495 pts with SCC of the oral cavity, oropharynx, hypopharynx, or larynx who had recurrence or PD after a platinum-containing regimen were randomized 1:1 to pembro 200 mg Q3W for 24 mo or investigator's choice of methotrexate, docetaxel, or cetuximab. Primary end point was OS in the ITT population. Key secondary end points included OS in the PD-L1 combined positive score (CPS) ≥1 population and PFS in the ITT and CPS ≥1 populations. OS and PFS in the PD-L1 tumor proportion score (TPS) ≥50% population were prespecified exploratory end points. Response was assessed per RECIST v1.1 by blinded, independent central review. Results: With full acquisition of survival data, HR was 0.80 (95% CI, 0.65-0.98) (nominal P = 0.0161) for OS and 0.96 (95% CI, 0.79-1.16) (nominal P = 0.33) for PFS in the ITT population. Median (95% CI) OS was 8.4 mo (6.4-9.4) for pembro vs 6.9 mo (5.9-8.0) for SOC; median PFS was 2.1 mo (2.1-2.3) vs 2.3 mo (2.1-2.8). Pembro benefit was greater in pts with PD-L1 CPS ≥1 and TPS ≥50% (Table). Conclusions: Pembro provided a clinically meaningful prolongation of OS compared with SOC in pts with R/M HNSCC. With full acquisition of survival data and compared with the previous analysis, the HR for OS decreased from 0.81 to 0.80, and the P value decreased from 0.0204 to 0.0161. There continued to be an enhanced benefit for pembro in pts with PD-L1–expressing tumors. Along with previously presented safety data, these results provide stronger support for the benefit of pembro in pts with R/M HNSCC. Table. OS and PFS in the PD-L1 CPS ≥1 and TPS ≥50% Populations CPS ≥1TPS ≥50%Pembron = 196SOCn = 191Pembro n = 64SOCn = 65OSMedian (95% CI), mo8.7 (6.9-11.4)7.1 (5.7-8.3)11.6(8.3-19.5)6.6(4.8-9.2)HR (95% CI)0.74 (0.58-0.93)0.53 (0.35-0.81)Pa0.00490.0014PFSMedian (95% CI), mo2.2 (2.1-3.0)2.3 (2.1-3.0)3.5(2.1-6.3)2.1(2.0-2.4)HR (95% CI)0.86 (0.69-1.06)0.58 (0.39-0.86)Pa0.080.003aNominal one-sided P value stratified by the randomization stratification factors. Citation Format: Denis Soulieres, Ezra Cohen, Christophe Le Tourneau, Jose Dinis, Lisa Licitra, Myung-Ju Ahn, Ainara Soria, Jean-Pascal Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Pingye Zhang, Jonathan Cheng, Ramona Swaby, Kevin J. Harrington. Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT115.

The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK

The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

360MO Pembrolizumab Plus Nab-Paclitaxel and Platinum As First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (R/M HNSCC): A Prospective Phase II Study

A Multicenter, Retrospective Study Analysis: Evaluating the Efficacy and Safety of Pembrolizumab in the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States

The Clinical Outcome of Pembrolizumab for Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: a Single Center, Real World Study in China

Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma

Sequential Treatment Use in Clinical Practice for U.S. Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study

A retrospective study evaluating the efficacy of pembrolizumab for metastatic or locally recurrent head and neck cancer: A real-world experience.

Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma

Pembrolizumab for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma in an Asian Population

Immune-checkpoint inhibitor plus chemotherapy conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis

Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial.

Immunotherapy for head and neck cancer: Recent advances and future directions

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised …

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

Real‐world first‐line treatment with pembrolizumab for non‐small cell lung carcinoma with high PD‐L1 expression: Updated analysis